Stanley Hsia to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Stanley Hsia has written about Dose-Response Relationship, Drug.
Connection Strength
0.092
-
Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 06; 406(10520):2631-2643.
Score: 0.047
-
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fern?ndez Land? L, Denning M, Ludwig L, Chen Y. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18; 393(11):1065-1076.
Score: 0.046